电子烟或雾化产品使用相关肺损伤(EVALI)的影像学、病理学、临床及生理学表现:不断演进的知识与遗留问题
本文综述电子烟或雾化产品使用相关肺损伤(EVALI)的影像与病理表现。EVALI为排除性诊断,需90天内使用史、排除其他病因且胸部影像异常;胸部CT最常见表现为急性肺损伤谱系,包括机化性肺炎和弥漫性肺泡损伤。准确快速识别可能通过积极临床管理和糖皮质激素给药降低发病率与死亡率。
要点
- EVALI为排除性诊断,需90天内使用史、排除其他病因且胸部影像异常。
- 胸部CT最常见表现为急性肺损伤谱系,包括机化性肺炎和弥漫性肺泡损伤。
- 病理表现取决于活检取样时疾病进程所处的阶段。
核心结论
- EVALI为排除性诊断,需90天内使用史、排除其他病因且胸部影像异常。
- 胸部CT最常见表现为急性肺损伤谱系,包括机化性肺炎和弥漫性肺泡损伤。
- 准确快速识别可能通过积极临床管理和糖皮质激素给药降低发病率与死亡率,糖皮质激素已显示可减轻部分患者肺损伤严重程度。
- 病理表现取决于活检取样时疾病进程所处的阶段。
研究设计与样本
- 本文为综述,总结该疾病的影像与病理表现,并列出若干尚未解答的主要问题。
关键影像表现/征象
- 胸部CT最常见表现为急性肺损伤谱系,包括机化性肺炎和弥漫性肺泡损伤。
- 其他较少见的肺损伤形式包括急性嗜酸性粒细胞性肺炎和弥漫性肺泡出血。
诊断标准与关键数值
- EVALI诊断需满足:患者有90天内近期雾化使用史、排除其他病因、胸部影像表现异常。
临床应用与阅片要点
- 放射科和病理科医生在疑似EVALI患者的评估中起重要作用。
- 准确快速识别可能通过积极临床管理和糖皮质激素给药降低发病率与死亡率。
局限性
- 本文为综述,列出若干尚未解答的主要问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Proposed as a safer alternative to smoking, the use of electronic cigarettes has not proven to be innocuous. With numerous deaths, there is an increasing degree of public interest in understanding the symptoms, imaging appearances, causes of, and treatment of electronic cigarette or vaping product use-associated lung injury (EVALI). Patients with EVALI typically have a nonspecific clinical presentation characterized by a combination of respiratory, gastrointestinal, and constitutional symptoms. EVALI is a diagnosis of exclusion; the patient must elicit a history of recent vaping within 90 days, other etiologies must be eliminated, and chest imaging findings must be abnormal. Chest CT findings in EVALI most commonly show a pattern of acute lung injury on the spectrum of organizing pneumonia and diffuse alveolar damage. The pathologic pattern found depends on when in the evolution of the disease process the biopsy sample is taken. Other less common forms of lung injury, including acute eosinophilic pneumonia and diffuse alveolar hemorrhage, have also been reported. Radiologists and pathologists help play an important role in the evaluation of patients suspected of having EVALI. Accurate and rapid identification may decrease morbidity and mortality by allowing for aggressive clinical management and glucocorticoid administration, which have been shown to decrease the severity of lung injury in some patients. In this review, the authors summarize the current state of the art for the imaging and pathologic findings of this disorder and outline a few of the major questions that remain to be answered.
引用
- Kligerman S, Raptis C, Larsen B, et al. Radiologic, Pathologic, Clinical, and Physiologic Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI): Evolving Knowledge and Remaining Questions. Radiology. 2020. PMID: 31990264. doi:10.1148/radiol.2020192585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。